Applied Filters
Kilpatrick Townsend hires litigation team from DLA Piper
Kilpatrick Townsend & Stockton has strengthened its life sciences expertise with the addition of a patent litigation team, that includes four litigators from DLA Piper.
Seventh Circuit urged to review AbbVie antitrust ruling
Twenty US states, the US Federal Trade Commission, and consumer groups have asked the Seventh Circuit of the US Court of Appeals to reconsider a case claiming that AbbVie strived to prevent competition to its immunosuppressant drug, Humira.
Novartis MS drug appeal upheld in Australia
The Federal Court of Australia has backed Novartis’ appeal against a decision revoking its patent covering a multiple sclerosis drug.
Fed Circuit reinstates $235m verdict against Teva
In a victory for GlaxoSmithKline, the US Court of Appeals for the Federal Circuit has revived a 2017 jury verdict ordering Teva to pay $235 million over the drug Coreg.
Celgene, Teva execs grilled over price hikes
A US House of Representatives committee has accused Teva and Celgene of imposing unjustified price hikes on blockbuster drugs Copaxone and Revlimid.
Collegium settles patent dispute with Teva
Massachusetts-based Collegium Pharmaceutical has reached a settlement agreement with Teva, resolving its patent litigation over pain medication.
Janssen sues Mylan to block generic of schizophrenia drug
A Johnson & Johnson company, Janssen Pharmaceuticals, is seeking a court order blocking Mylan from making copies of its schizophrenia treatment, Invega Trinza, until its patent expires in 2036.
Bausch Health settles with Sun Pharma
Canada-based Bausch Health has dropped its litigation against Indian generic maker Sun Pharma as part of a settlement agreement.
BMS and Dr Reddy’s settle Revlimid suit with generics licence
Bristol Myers Squibb and Celgene have settled their patent litigation with Dr Reddy’s over a generic version of cancer drug Revlimid.
Gilead accused of illegally paying to delay HIV drug competition
Biopharmaceutical company Gilead is being sued for allegedly scheming to prevent a generic rival from releasing a competing version of its HIV drug Truvada, according to a class action lawsuit filed by investors in the drug manufacturer.
